Shares of Heska Corp (NASDAQ:HSKA) have been given an average recommendation of “Hold” by the ten brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $84.25.

Several equities analysts recently issued reports on HSKA shares. Zacks Investment Research cut Heska from a “hold” rating to a “sell” rating in a report on Friday, November 15th. Canaccord Genuity restated a “buy” rating and set a $105.00 target price (up previously from $75.00) on shares of Heska in a report on Wednesday, November 6th. Raymond James cut Heska from an “outperform” rating to a “market perform” rating in a report on Thursday, November 7th. They noted that the move was a valuation call. BidaskClub cut Heska from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, ValuEngine cut Heska from a “strong-buy” rating to a “buy” rating in a report on Friday, January 3rd.

A number of institutional investors and hedge funds have recently modified their holdings of HSKA. FMR LLC boosted its holdings in Heska by 2.0% during the first quarter. FMR LLC now owns 453,664 shares of the medical research company’s stock worth $38,616,000 after buying an additional 8,870 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Heska by 1,229.0% during the second quarter. JPMorgan Chase & Co. now owns 21,876 shares of the medical research company’s stock worth $1,834,000 after buying an additional 20,230 shares during the last quarter. Bank of Montreal Can boosted its holdings in Heska by 30.3% during the second quarter. Bank of Montreal Can now owns 2,162 shares of the medical research company’s stock worth $183,000 after buying an additional 503 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Heska by 6.2% during the second quarter. Charles Schwab Investment Management Inc. now owns 41,417 shares of the medical research company’s stock worth $3,528,000 after buying an additional 2,423 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Heska by 2.6% during the second quarter. Northern Trust Corp now owns 159,007 shares of the medical research company’s stock worth $13,543,000 after buying an additional 4,021 shares during the last quarter. Hedge funds and other institutional investors own 98.43% of the company’s stock.

Heska stock traded down $2.27 during mid-day trading on Thursday, hitting $105.66. The stock had a trading volume of 129,860 shares, compared to its average volume of 92,443. The stock has a 50-day simple moving average of $97.18 and a two-hundred day simple moving average of $82.89. The stock has a market capitalization of $844.91 million, a PE ratio of 224.81 and a beta of 1.10. Heska has a 12 month low of $62.47 and a 12 month high of $110.90. The company has a current ratio of 8.52, a quick ratio of 6.80 and a debt-to-equity ratio of 0.31.

Heska (NASDAQ:HSKA) last posted its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). The business had revenue of $31.24 million for the quarter, compared to analysts’ expectations of $30.44 million. Heska had a return on equity of 3.17% and a net margin of 3.15%. Sell-side analysts expect that Heska will post 0.05 earnings per share for the current fiscal year.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

Read More: How much money do you need to begin day trading?

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.